News

“We are excited to work with the leading heart valve centers in the U.S. to offer more patients suffering from tricuspid regurgitation a treatment option. The initiation of the TANDEM II Early Feasibility Study is an important milestone as we expand the clinical evidence for the DUO™ System”

CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation, announced today the closing of $16 million Series B financing.

W. Wojakowski , New York Valves Jun 2024

With Edwards and Abbott making recent waves in the tricuspid regurgitation (TR) treatment space, CroíValve hopes to pave its own way.

Martin B. Leon, MD appointed as chair of CroiValve's clinical advisory board

Wojciech Wojakowski presented First in Human Experience with the CroíValve DUO Novel Tricuspid Coaptation Valve TANDEM I Trial on 9th Jun ’23 at TVT, Phoenix, US.

Implanting team at the National Institute of Cardiology in Warsaw with Prof Adam Witkowski and Dr Maciej Dąbrowski